摘要
脑得生片(丸)为药典方,由三七、川芎、红花、葛根、山楂(去核)组成,具有活血化瘀,疏通经络,醒脑开窍的功效,用于脑动脉硬化,缺血性脑中风及脑出血后遗症。本课题系统地研究了复方脑得生有效成分的提取、精制以及复方脑得生口服液成型工艺、稳定性的评价,研制出了疗效确切、作用迅速、质量稳定、口感好的脑得生口服液剂型。
在制备工艺的研究中:在方中各味药的提取实验中,采用正交实验的方法,运用分光光度计为检测手段,以三七总皂苷为定量指标,优选了三七的醇提取工艺;运用高效液相法,以葛根素为定量指标,拟定葛根、川芎、山楂、红花及三七醇提后残渣的水提条件;用沉淀法分别对三七醇提液和五味药材的水提液进行了精制;将精制液合并,加入PH调节剂,并用高速离心的方法对药材的精制液进行进一步纯化后,加入矫味剂,灌封、灭菌制得脑得生口服液。
在质量标准的研究中:对川芎、红花、葛根等药进行了薄层定性鉴别,斑点分离效果好、阴性对照无干扰,证明所选方法专属性强;含量测定采用HPLC梯度洗脱法测定方中君药三七主要有效成分三七皂苷R_1、人参皂苷Rg_1、人参皂苷Rb_1的含量,测得加样回收率分别为100.35%(RSD=1.69%),99.95%(RSD=1.26%),100.32%(RSD=1.38%),含量分别不低于0.234mg/ml,0.957mg/ml,0.477mg/ml;通过初步稳定性试验证明工艺合理可行,质量稳定、可控。
本研究以中医药理论为指导,采用现代技术为实验手段,为脑得生开发新剂型提供质量评价方法,为脑得生口服液工业大生产提供了科学依据,为新药开发研究奠定了良好的基础。
The formula of Naodesheng tablet(pill) comes from Chinese Pharmacopoeia, which is made of several Chinese herbs, including Radix Notoginseng, Rhizoma Ligustici Chuanxiong, Flos Carthami, Radix Puerariae and Fructus Crataegi. The major effects of this medicine include reducing stasis and improving blood circulation, mediating main and collateral channels, and regaining consciousness. It is a remedy for cerebral arteriosclerosis, stroke and sequelae of cerebral hemorrhage. The topic systematically reseach on extraction, purifying the effective component of Naodesheng, on the molding process, and on the appraisal of stability, which has achieved the topic design goal.
In this research, orthogonal method was designed to screen the extraction procedure of all drug components to get the best one. Quantitative analysis was carried out on total notoginseng saponin, puerarin by spectrophotometer method, HPLC to ensure quality control of NDS oral liquid.
When we studied the quality standard, we used the TLC to identify the Rhizona Ligustici Chuanxiong, Flos Carthami, radix puerariae respectively, the separation of the stains was apparent and the negative contrast was not disturbed. All of these proved that the method we used is specific. We used HPLC gradient elution method to determination the amount of Notoginsenoside R_1, Ginsenoside Rg_1 and Rb_1 in Naodesheng Oral Liquid. Their average recoveries: Notoginsenoside R_1 was 100.35% (RSD=1.69%) , Ginsenoside Rg_1 was99.95%(RSD=1.26%) and Ginsenoside Rb_1 was 100.32% (RSD=1.38%) , respectively. Through the tentative stability of Naodesheng, all of the results showed that the preparing technology is rational and the quality of this medicine is stable.
In this research, under the guidance of the Chinese medicinal theory and practice, new technology was used as experimental method. The experiment will provide the drug efficacy and quality control evaluation standards for NDS new drug form, provide the scientific foundation for the big industry's production, set a good foundation for the research and exploration of new medicine.
引文
[1] 章翔.脑卒中诊断治疗学,北京:人民军医出版社,2002,第一版:2
[2] 国家药典委员会.中华人民共和国药典.2005年版.一部.北京:化学工业出版,2005.1:572
[3] 刘云等.脑得生片合血塞通注射液治疗中风30例[J].江苏中医,2001,22(8):20
[4] 杨志刚,陈阿琴,俞颂东.三七药理研究新进展.上海中医药杂志,2005,39(4):60
[5] Zhu HB, Wang ZH, et a.l Neuroprotective effects of hydroxysafflor yellow A; In vivo and in vitro studies[J]. Planta Med, 2003, 69(5): 429
[6] 桂卉.HPLC 考察川芎茶调颗粒制备中川芎嗪的动态变化[J].中成药,2003,25(4):279
[7] 何晶.三七的药理作用[J].首都医药,2004,(18):39
[8] 潘旭初.三七总皂苷的提取工艺[J].数理医药学杂志,2003,16(5):437~438
[9] 杨志刚,陈阿琴,俞颂东.三七药理研究新进展.上海中医药杂志,2005,39(4):60
[10] 刘建辉,翼风云,王亭,等.三七总皂苷对实验性脑缺血脑血流及血脑屏障的影响作用[J].河北医药,2002,24(4):249
[11] 姚小皓,李学军.三七中人参三醇苷对脑缺血的保护作用及其机制[J].中国中药杂志,2002,27(5):371~373
[12] 许军,王阶,温林军.三七总皂甙干预血栓形成研究概况.云南中医中药杂志,2003,24(5):46
[13] 何晶.三七的药理作用及研究进展[J].天津药学,2004,16(5):58
[14] 施峰,刘焱文.红花的化学成分及药理研究进展[J].时珍国医国药,2006,17(9):1666
[15] 周平兰,夏新华.红花黄色素提取工艺的研究[J].湖南中医学院学报,2004,24(1):11
[16] 田京伟,傅风华,蒋王林,等.羟基红花黄色素A对脑缺血所致大鼠脑线粒体损伤的保护作用[J].药学学报,2004,39(10):774
[17] 梁辉,范金英,李爱华,等.羟基红花黄色素A对大鼠局灶性脑缺血再灌注NMDAR_1蛋白表达的影响[J].中华老年心脑血管病杂志,2004,6(3):194.
[18] 蒋永福,张煜,方岩雄,王弧莉.葛根的研究及应用进展[J].广州化工,2002,30(4):31~32
[19] 张新广,王冬梅.葛根素提取工艺的研究[J].中药材,2004,27(9):682
[20] 崔树明.中药葛根的药理研究及进展[J].内蒙古中医药.2005,(1):58
[21] 潘洪平.葛根总黄酮和葛根素的药理进展[J].广西医学,2003,25(10):1941
[22] 朱毅,赵赤,李灵芝.葛根素对脑药理作用的研究进展[J].武警医学院学报2005,14(5):426
[23] 李秋怡,干国平,刘焱文.川芎的化学成分及药理研究进展[J].时珍国医国药,2006,17(7):1298
[24] 李秋怡,干国平,刘焱文.川芎的化学成分及药理研究进展[J].时珍国医国药2006,17(7):1299
[25] 岑得意,陈志武,宋必卫,等.川芎嗪对大鼠脑梗塞的保护作用[J].中国药理学通报,1999,15(5):464
[26] 陈洁文,汤湘江,万文成.川芎嗪对大鼠脑急性脑缺血缺氧损伤的保护作用[J].广州中医药大学学报,1998,15(1):60~63
[27] 翁毅力.山楂的药理作用[J].中国药业,2005,14(12):89
[28] 姜开余,顾振纶,阮长耿.WH505对实验性血栓形成的影响及其他作用机制[J].中成药,2000,22(11):782
[29] 李义奎.中药药理学[M].北京:中国中医药出版社,1992:126-126
[30] 范碧亭.中药药剂学.第一版.上海科学技术出版社,1997:153